Editor’s Note: The title of the story is updated to correct the reference to ‘Breast’ cancer instead of ‘Lung’ cancer. Tuesday, Merck & Co Inc (NYSE:MRK) released topline data from hase 3 KEYNOTE-522 ...
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Merck (NYSE:MRK) has ended acquisition talks with Revolution Medicines after the ...
Merck (NYSE:MRK) received FDA approval for KEYTRUDA and its subcutaneous formulation QLEX for platinum-resistant ovarian cancer. The FDA also approved a companion diagnostic to help identify patients ...
Keytruda demonstrated statistically significant and clinically meaningful improvement in OS compared to pre-operative chemotherapy. KEYNOTE 522 is the fourth study of a Keytruda-based regimen in an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results